<DOC>
	<DOCNO>NCT01694602</DOCNO>
	<brief_summary>The overall aim research develop non-invasive approach evaluate production 3-methylhistidine ( 3MH ) cancer patient , potential mean determine patient high risk future development cancer induce skeletal muscle atrophy . Rationale : The approach base hypothesis oral dose deuterated 3-methylhistidine ( D-3MH ) , slope terminal portion decay curve ( &gt; 12 hour post-dosing ) tracer/tracee ( D-3MH/3MH ) free 3MH pool proportional rate constant myofibrillar protein degradation determine spot urine sample .</brief_summary>
	<brief_title>Non-Invasive Assessment Skeletal Muscle Loss Cancer Patients - Phase II</brief_title>
	<detailed_description>The long-term objective research develop non-invasive approach assessment de novo 3MH production cancer patient early course disease way assess patient high risk future development skeletal muscle atrophy . The approach base : 1 ) know increase de novo production 3-methylhistidine ( 3MH ) muscle protein breakdown say patient consequence unique disease-host interaction , 2 ) early demonstration de novo 3MH production measure vivo use isotope dilution . During Phase-II project , propose conduct statistically powerful prospective investigation demonstrate measurement slope terminal decay curve ( rate constant ) approach newly diagnose cancer patient predict future development muscle waste . We expect outcome combined Phase-I Phase-II research lead early identification elevate muscle catabolism at-risk patient medical intervention prevent future muscle atrophy .</detailed_description>
	<mesh_term>Cachexia</mesh_term>
	<criteria>( 1 ) histological cytological evidence NSCLC without curative option ; ( 2 ) 18 year age ; ( 3 ) patient report weight loss ≤5 % usual body weight last 6 month ; ( 4 ) life expectancy great 6 month base judgement treat physician ; ( 5 ) serum creatinine ≤1.5 time upper limit normal ; ( 6 ) willing able give inform consent . 1 ) malabsorption , intractable vomit gastrointestinal obstruction 2 ) congestive heart failure 3 ) edema ascites 4 ) liver function test result preclude administration prescribe therapy 5 ) pregnant , nursing , , childbearing age , unwilling use contraceptive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Cachexia</keyword>
	<keyword>Sarcopenia</keyword>
	<keyword>De Novo</keyword>
	<keyword>Deuterated</keyword>
</DOC>